Literature DB >> 1314126

Small cell carcinoma with two paraendocrine syndromes.

S T Pierce1, M Metcalfe, E R Banks, M E O'Daniel, P DeSimone.   

Abstract

Simultaneous elevated levels of ectopic arginine vasopressin (AVP) and ectopic adrenocorticotropin (ACTH) were found in a patient with small cell carcinoma (SCC). The finding of one of these paraendocrine syndromes at the time of diagnosis is common; however, the simultaneous presence of both syndromes has been reported in the literature only on four occasions in the past 25 years. This is the only report in which elevated plasma levels of both hormones are documented in a patient who simultaneously fulfills the criteria for the syndrome associated with each ectopically produced peptide. In the English-language literature, this is the first case that demonstrates by immunohistochemical staining the presence of both of these hormones in the patient's neoplasm. In addition to the use of radiographs, the presence of paraendocrine disorders can provide a method of monitoring the patient's response to therapy. The levels of ACTH and AVP were assayed during this patient's course and correlated with disease refractory to therapy, resulting in poor survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314126     DOI: 10.1002/1097-0142(19920501)69:9<2258::aid-cncr2820690908>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report.

Authors:  Kristin Coners; Scott E Woods; Michael Webb
Journal:  J Med Case Rep       Date:  2011-07-19

2.  Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications.

Authors:  Krishna Adit Agarwal; Myat Han Soe
Journal:  Case Rep Oncol Med       Date:  2018-10-18

3.  Long-term Survival of a Patient with Small Cell Lung Cancer Secreting ADH and ACTH Simultaneously, Following the Prolonged Use of Amrubicin.

Authors:  Aya Kosuda; Toru Shirahata; Nasa Kudo; Yuki Uehara; Masayoshi Miyawaki; Aika Hagiwara; Rie Murakami; Ken Shimizu
Journal:  Intern Med       Date:  2019-09-11       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.